Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
15.04.Pulmocide exits OPERA with phase 2 evidence of antifungal safety and efficacy
15.04.Neumora's schizophrenia drug faces FDA hold over convulsions in rabbits
15.04.MaaT, eyeing 2026 launch for microbiome therapy, posts 18-month data in aGvHD
12.04.Roche picks up Prenosis' newly cleared sepsis AI tool for distribution
12.04.Genentech axes Adaptimmune cell therapy deal as it presses ahead with staff cuts
12.04.Portage Biotech hints at potential closure as it halts programs, hunts for strategic options
12.04.Illumina gets go-ahead from European Commission to part ways with Grail
12.04.Enlivex defends sepsis data that sank stock, shifting focus from mortality to subgroup analysis
12.04.Novartis may have bought MorphoSys, but it really only had eyes for BET inhibitor pelabresib: filing
11.04.Peak Rock Capital takes a bite out of Steris with $787M dental business deal
11.04.Alzheimer's blood test from Roche & Eli Lilly nabs FDA breakthrough tag
11.04.Double autoimmune acquisitions as Century, Eliem each pick up peers
11.04.Novartis pays $150M for Arvinas' phase 3-ready prostate cancer protein degrader
11.04.AACR: Verastem, Quanta and Frontier demonstrate KRAS inhibitors' potential in preclinical data
10.04.Nearly a week after pulling Relyvrio, Amylyx to engage regulators about the drug's path in another rare disease
10.04.Philips plots return to US sleep apnea market after final consent decree in CPAP recall
10.04.AACR: To bring CAR-T to solid tumors, Poseida thinks we need to boost conditioning therapy
10.04.AACR: Synthekine hopes new IL-2 will be the high-alpha in a beta class
10.04.Bristol Myers-backed TORL secures $158M to march army of ADCs through clinic
09.04.Alcanza acquires Innovation Medical Research Center location outside Miami
09.04.MMI's Symani microsurgery robot secures de novo clearance from FDA
09.04.ACC: Medtronic heart valve shows benefits in head-to-head TAVR study focused on women
09.04.YS Biopharma's rabies vaccine bests approved competitor in interim phase 3 readout
09.04.Karuna's captains set sail in new neuropsychiatric venture called Seaport Therapeutics
09.04.BrainStorm, plotting Lazerus-like recovery, aligns with FDA on design of phase 3b ALS trial